Welcure Drugs & Pharmaceuticals Ltd

Welcure Drugs & Pharmaceuticals Ltd has reached a new 52-week and all-time low price of Rs.0.25, marking a significant decline in its stock value amid broader market pressures and company-specific factors.

Welcure Drugs & Pharmaceuticals Ltd has reached a new 52-week and all-time low of Rs.0.26 today, marking a significant decline in its stock price amid a challenging market environment. This latest low reflects a year-long downward trend, with the stock underperforming its sector and benchmark indices.

Welcure Drugs & Pharmaceuticals Ltd has reached a new 52-week and all-time low of Rs.0.27, marking a significant decline in its stock price amid broader market weakness and sectoral pressures.

Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Welcure Drugs & Pharmaceuticals Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive valuation grade. This change is underscored by its exceptionally low price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to both its historical averages and peer group benchmarks, signalling a potential opportunity for value investors amid a challenging market backdrop.

Welcure Drugs & Pharmaceuticals Ltd has reported a mixed quarterly performance for December 2025, reflecting a shift from very positive to positive financial trends. While net sales and profit after tax (PAT) have shown robust growth over the last six months, recent quarterly margins have contracted sharply, signalling operational challenges despite top-line momentum.

Welcure Drugs & Pharmaceuticals Ltd. reported a catastrophic operational collapse in Q3 FY26, with net sales plummeting to zero from ₹65.62 crores in the previous quarter, whilst the micro-cap pharmaceutical company posted a net profit of ₹1.07 crores entirely driven by non-operating income. The stock, trading at ₹0.36 with a market capitalisation of just ₹44.49 crores, has crashed 56.52% over the past year and now trades 74.83% below its 52-week high of ₹1.43, reflecting severe investor concerns about business viability.

Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 07 February 2026, providing investors with the most up-to-date insight into the stock’s fundamentals, valuation, financial trends, and technical outlook.

Welcure Drugs & Pharmaceuticals Ltd has touched a new 52-week and all-time low of Rs.0.28, marking a significant decline in its stock price amid a challenging market environment. This latest low reflects a steep downturn over the past year, with the stock underperforming its sector and benchmark indices.

Welcure Drugs & Pharmaceuticals Ltd’s stock touched a new 52-week and all-time low of Rs.0.28 today, marking a significant decline amid a challenging market environment. This fresh low comes after a prolonged downtrend, reflecting ongoing pressures on the company’s valuation and performance metrics.

Welcure Drugs & Pharmaceuticals Ltd has touched a new 52-week and all-time low of Rs.0.29 today, marking a significant decline in its stock price amid a challenging market environment and company-specific factors.

Welcure Drugs & Pharmaceuticals Ltd has reached a new 52-week and all-time low price of Rs.0.3, marking a significant decline amid a broader market environment where the Sensex trades positively. The stock’s recent performance reflects a series of challenges impacting its valuation and investor sentiment.

Welcure Drugs & Pharmaceuticals Ltd has touched a new 52-week low of Rs.0.31, marking a significant decline in its stock price amid a broader market environment where the Sensex remains relatively resilient. The stock’s recent performance reflects a series of downward movements, culminating in this fresh low point.

Welcure Drugs & Pharmaceuticals Ltd has reached a new 52-week and all-time low of Rs.0.32, marking a significant decline in its stock price amid broader market fluctuations and sectoral underperformance.

Welcure Drugs & Pharmaceuticals Ltd has reached a new 52-week low of Rs.0.33, marking a significant decline in its stock price amid broader market gains. This fresh low reflects ongoing pressures on the stock, which has underperformed its sector and the benchmark Sensex over the past year.